RVMD
NASDAQ HealthcareRevolution Medicines, Inc. - Common Stock
Biotechnology
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
�� 市场数据
| 价格 | $151.31 |
|---|---|
| 成交量 | 3,679,545 |
| 市值 | 32.17B |
| 贝塔系数 | 1.410 |
| RSI（14日） | 55.6 |
| 200日均线 | $88.19 |
| 50日均线 | $132.59 |
| 52周最高 | $166.50 |
| 52周最低 | $34.00 |
| Forward P/E | -26.84 |
| Price / Book | 20.19 |
🎯 投资策略评分
RVMD 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (87/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🔪 Falling Knife (10/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 RVMD in your text
粘贴任何文章、记录或帖子 — 工具将提取 RVMD 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.